Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Registration Number
- NCT00035048
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
- Detailed Description
The duration of treatment is 10 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 540
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method HAMD-17 score </= 10 after 10 weeks; maintenance of antidepressant effect for 6-10 months; tolerability After 10 weeks & 6-10 months
- Secondary Outcome Measures
Name Time Method CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; MADRS total score change at Month 6, HAMA total score change at Month 6 6 Months